Saturday 17 October 2026
Export ECOR’s income statement to Excel — free account
electroCore, Inc.
ECOR Healthcare Medical Devices
electroCore, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $32.0 million, up 27.2% from fiscal 2024. In the quarter to June 2026, revenue grew 28.0%, EPS grew 25.0% and free cash flow fell 443.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
7.85
0.50
−5.99%
Follow ECOR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.20 | 1.55 | 1.19 | 1.40 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(23.10) | (17.95) | (24.73) | (25.05) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.09 | 1.49 | 1.04 | 1.18 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(7.93) | (7.58) | (4.05) | (4.46) | |
EV/FCF |
(7.92) | (7.55) | (4.02) | (4.40) | |
Quick Ratio |
0.94 | 0.79 | 1.11 | 1.21 | |
Current Ratio |
1.21 | 1.02 | 1.38 | 1.43 | |
Net Debt/EBITDA |
1.59 | 0.41 | 1.57 | 2.94 | |
Debt/Assets |
33.80% | 43.19% | 35.39% | 30.48% | |
Debt/Equity |
(2.07) | (1.18) | (3.87) | (6.08) | |
Asset Turnover |
2.34 | 2.21 | 1.64 | 1.41 | |
Operating CF/Net income |
1.15 | 0.57 | 0.51 | 0.49 | |
Capex/Depreciation |
(0.05) | (0.02) | 0.00 | (0.01) | |
Interest Coverage |
(8.64) | (16.72) | (7.91) | (13.87) | |
Research and Development Expense of Revenue |
8.66% | 7.72% | 9.95% | 7.62% | |
Selling, General and Administrative Expense of Revenue |
107.21% | 135.02% | 110.26% | 111.54% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
7.99% | 10.81% | 5.08% | 4.78% | |
Graham Net Nets |
(0.07) | (0.16) | (0.12) | (0.12) | |
Graham Number |
3.33 | 5.03 | 2.73 | 2.21 | |
Earnings Yield |
(19.21%) | (29.35%) | (36.75%) | (34.55%) | |
Free Cash Flow Yield |
(11.99%) | (12.73%) | (21.67%) | (19.16%) | |
Revenue per Share |
1.00 | 1.07 | 1.09 | 1.03 | |
Operating CF per Share |
(0.37) | (0.34) | (0.18) | (0.20) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.37) | (0.34) | (0.18) | (0.20) | |
Cash per Share |
1.07 | 0.99 | 1.37 | 1.56 | |
Shareholders Equity per Share |
(0.30) | (0.64) | (0.20) | (0.13) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.30) | (0.64) | (0.20) | (0.13) | |
Free Cash Flow |
(3.52) | (3.01) | (1.54) | (1.67) | |
Working Capital |
2.45 | 0.21 | 4.32 | 5.21 | |
Capital Expenditures |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Current Asset Value |
(5.73) | (8.64) | (4.71) | (5.14) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.86 | 1.17 | 1.20 | 1.02 | |
Average Payables |
2.37 | 1.97 | 2.27 | 2.16 | |
Average Inventory |
1.92 | 1.86 | 1.65 | 1.58 | |
Average Assets |
15.81 | 15.76 | 19.57 | 21.23 | |
Average Common Equity |
(0.84) | (0.66) | 2.92 | 4.19 |
Columns are period end dates